Products
Brenetafusp Biosimilar TCR–scFv Fusion Protein (CD3) for Research
Cat No.: GMP-Bios-INN-1110
Anti-CD3 therapeutic antibody (Pre-made Brenetafusp biosimilar,Fusion Protein (scFv fused to TCR Fab)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Brenetafusp (development code IMC-F106C) is a T-cell receptor bispecific fusion protein (ImmTAC) targeting the PRAME antigen presented by HLA-A*02:01 and CD3. It is developed by Immunocore for melanoma and other solid tumors. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1110-1mg | 1mg | 3090 |
| GMP-Bios-INN-1110-10mg | 10mg | |
| GMP-Bios-INN-1110-100mg | 100mg | |
| GMP-Bios-INN-1110-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Brenetafusp biosimilar, Fusion Protein (scFv fused to TCR Fab) targeting CD3: Recombinant therapeutic protein targeting CD3/CD3E/CD3e/T-cell surface glycoprotein CD3 epsilon chain |
| INN Name | Brenetafusp |
| Target | CD3 |
| Format | Fusion Protein (scFv fused to TCR Fab) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Immunocore |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma;Solid tumours;Endometrial cancer;Non-small cell lung cancer;Ovarian cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
